FGF2

Across TCGA pan-cancer cohorts, FGF2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of FGF2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where FGF2 RNA is repressed in tumor relative to normal tissue. In most cancer types FGF2 is over-expressed in tumor, although a few such as BLCA and LUSC show the opposite, repressed pattern.

BLCA, LUSC, and LUAD are the cancer types where FGF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−2.614	<.001	11	view →
LUSC	All	III,IV	−1.808	<.001	9	view →
LUAD	Female	III,IV	−1.787	<.001	9	view →
COAD	Male	II,III,IV	−1.110	<.001	9	view →
KICH	Female	III,IV	−3.410	<.001	8	view →
UCEC	All	All	−3.594	<.001	6	view →
BRCA	All	III,IV	−3.065	<.001	6	view →
STAD	All	All	−1.165	.001	5	view →
THCA	All	All	+0.496	<.001	3	view →
READ	Female	All	−2.087	.005	2	view →
LIHC	Male	II,III,IV	+1.084	.006	2	view →
PRAD	All	All	−0.890	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

FGF2–BLCA

Open the BLCA breakdown →